Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections:Cost-effectiveness analyses and implications for the Netherlands

We performed a review of cost-effectiveness of elderly pneumococcal vaccination to prevent invasive disease. It concerns studies in the USA, Canada, Netherlands and Spain and a multinational study of five European countries. Cost-effecfiveness of elderly vaccination against invasive pneumococcal infections varies from cost-saving to €33,000 per life-year gained. The Dutch study estimates cost-effecfiveness at €10,100 per life-year gained (price level: 1995). This is below the level that has recently been defined for treatment of high cholesterol (€20,000 per life-year gained) and may therefore... Mehr ...